Impact Of Molecular Prescreening For Genomically-Guided Trials In Head And Neck Cancer (Hnc).

6030Background: HNC encompass a group of highly heterogeneous diseases, including oral, oropharyngeal and laryngeal squamous cell carcinomas (SCC), nasopharyngeal (NP), nasosinusal (NS) and salivary gland (SG) tumors. Chemotherapy has shown limited efficacy in recurrent (rec)/metastatic (met) disease. Genomic studies have increased our understanding of HNC biology, identifying potential targetable mutations (mut). We evaluated the impact of precision medicine efforts in HNC at Vall d’Hebron Institute of Oncology (VHIO). Methods: From 10/2010 to 10/2015, 49 patients (pts) with metastatic HNC underwent tumor molecular profiling at VHIO. Mut detection was performed using multiplex mass-spectrometry (Sequenom, n = 21) or NGS (AmpliconSeq, n = 28).Profiling was performed on metastatic (n = 21) or primary sites (n = 19), with missing information in remaining cases (n = 9). Results: Most frequent tumor type was SCC (n = 20), followed by SG (n = 18), NP (n = 9) and NS (n = 2). Median age at diagnosis was 51 years...